Details of the Drug

General Information of Drug (ID: DMQMBZ1)

Drug Name
Rivaroxaban
Synonyms XARELTO (TN)
Indication
Disease Entry ICD 11 Status REF
Deep vein thrombosis BD71 Approved [1]
Heparin-induced thrombocytopenia 3B64.12 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Affected Organisms
Humans and other mammals
ATC Code
B01AF01: Rivaroxaban
B01AF: Direct factor Xa inhibitors
B01A: ANTITHROMBOTIC AGENTS
B01: ANTITHROMBOTIC AGENTS
B: BLOOD AND BLOOD FORMING ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 435.9
Logarithm of the Partition Coefficient (xlogp) 2.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.4 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 hours [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.06% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.7 L/kg [4]
Chemical Identifiers
Formula
C19H18ClN3O5S
IUPAC Name
5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
Canonical SMILES
C1COCC(=O)N1C2=CC=C(C=C2)N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
InChIKey
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
Cross-matching ID
PubChem CID
9875401
ChEBI ID
CHEBI:68579
CAS Number
366789-02-8
UNII
9NDF7JZ4M3
DrugBank ID
DB06228
TTD ID
D0KG3R
VARIDT ID
DR00227
INTEDE ID
DR1431
ACDINA ID
D00601
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Modulator [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [6]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [9]
Cytochrome P450 2J2 (CYP2J2) DERSX5P CP2J2_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Biotransformations [10]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Biotransformations [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Deep vein thrombosis
ICD Disease Classification BD71
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Coagulation factor Xa (F10) DTT F10 4.84E-02 -0.28 -0.9
P-glycoprotein 1 (ABCB1) DTP P-GP 2.04E-02 -1.13E+00 -1.00E+00
Breast cancer resistance protein (ABCG2) DTP BCRP 2.10E-01 3.71E-01 7.59E-01
Cytochrome P450 2J2 (CYP2J2) DME CYP2J2 1.81E-19 1.37E+00 4.29E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.51E-02 1.53E+00 1.16E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.84E-01 -1.61E-01 -3.61E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rivaroxaban
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Rivaroxaban and Danaparoid. Deep vein thrombosis [BD71] [11]
Coadministration of a Drug Treating the Disease Different from Rivaroxaban (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Rivaroxaban caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [12]
Midostaurin DMI6E0R Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [13]
Arn-509 DMT81LZ Major Increased metabolism of Rivaroxaban caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [15]
Emapalumab DMZG5WL Moderate Altered metabolism of Rivaroxaban due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [13]
Siltuximab DMGEATB Moderate Altered metabolism of Rivaroxaban due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [13]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Rivaroxaban caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [15]
Ag-221 DMS0ZBI Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [15]
Erdafitinib DMI782S Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [16]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Rivaroxaban caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [12]
Tucatinib DMBESUA Moderate Decreased metabolism of Rivaroxaban caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [15]
PF-04449913 DMSB068 Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [13]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Rivaroxaban and Levomilnacipran. Chronic pain [MG30] [17]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Rivaroxaban and Regorafenib. Colorectal cancer [2B91] [13]
Intedanib DMSTA36 Moderate Increased risk of bleeding by the combination of Rivaroxaban and Intedanib. Colorectal cancer [2B91] [18]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Rivaroxaban and Ardeparin. Coronary thrombosis [BA43] [11]
Lumacaftor DMCLWDJ Major Increased metabolism of Rivaroxaban caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [14]
Ivacaftor DMZC1HS Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [12]
MK-8228 DMOB58Q Moderate Decreased metabolism of Rivaroxaban caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [15]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Rivaroxaban and Vilazodone. Depression [6A70-6A7Z] [17]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Rivaroxaban and Vortioxetine. Depression [6A70-6A7Z] [17]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Rivaroxaban and Desvenlafaxine. Depression [6A70-6A7Z] [17]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Rivaroxaban and Apigenin. Discovery agent [N.A.] [19]
Stiripentol DMMSDOY Moderate Decreased metabolism of Rivaroxaban caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Tazemetostat DMWP1BH Major Increased risk of bleeding by the combination of Rivaroxaban and Tazemetostat. Follicular lymphoma [2A80] [12]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Rivaroxaban and Avapritinib. Gastrointestinal stromal tumour [2B5B] [13]
Boceprevir DMBSHMF Major Decreased metabolism of Rivaroxaban caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [15]
GS-5885 DMSL3DX Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [20]
Fostemsavir DM50ILT Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [21]
Cobicistat DM6L4H2 Major Decreased clearance of Rivaroxaban due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [15]
Etravirine DMGV8QU Moderate Increased metabolism of Rivaroxaban caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [12]
BMS-201038 DMQTAGO Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [12]
Suvorexant DM0E6S3 Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Suvorexant. Insomnia [7A00-7A0Z] [12]
Crizotinib DM4F29C Moderate Decreased metabolism of Rivaroxaban caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
Brigatinib DM7W94S Moderate Increased metabolism of Rivaroxaban caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [12]
Ceritinib DMB920Z Moderate Decreased metabolism of Rivaroxaban caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [15]
PF-06463922 DMKM7EW Moderate Accelerated clearance of Rivaroxaban due to the transporter induction by PF-06463922. Lung cancer [2C25] [12]
Capmatinib DMYCXKL Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [22]
Selpercatinib DMZR15V Moderate Decreased metabolism of Rivaroxaban caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Rivaroxaban and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [23]
Idelalisib DM602WT Moderate Decreased metabolism of Rivaroxaban caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [15]
IPI-145 DMWA24P Moderate Decreased metabolism of Rivaroxaban caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [15]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Rivaroxaban and Acalabrutinib. Mature B-cell lymphoma [2A85] [24]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Rivaroxaban and Ibrutinib. Mature B-cell lymphoma [2A85] [25]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Rivaroxaban and Ponatinib. Mature B-cell lymphoma [2A85] [26]
Vemurafenib DM62UG5 Moderate Increased metabolism of Rivaroxaban caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [12]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Rivaroxaban caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [12]
Lasmiditan DMXLVDT Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Lasmiditan. Migraine [8A80] [27]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Rivaroxaban and Panobinostat. Multiple myeloma [2A83] [15]
Fedratinib DM4ZBK6 Major Increased risk of bleeding by the combination of Rivaroxaban and Fedratinib. Myeloproliferative neoplasm [2A20] [12]
Ruxolitinib DM7Q98D Major Increased risk of bleeding by the combination of Rivaroxaban and Ruxolitinib. Myeloproliferative neoplasm [2A20] [12]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Rivaroxaban and Vorapaxar. Myocardial infarction [BA41-BA43] [28]
Rolapitant DM8XP26 Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [29]
Netupitant DMEKAYI Moderate Decreased metabolism of Rivaroxaban caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [15]
Entrectinib DMMPTLH Moderate Decreased metabolism of Rivaroxaban caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [30]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Rivaroxaban and Nepafenac. Osteoarthritis [FA00-FA05] [31]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Rivaroxaban caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [32]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Rivaroxaban and MK-4827. Ovarian cancer [2C73] [13]
Abametapir DM2RX0I Moderate Decreased metabolism of Rivaroxaban caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [33]
Lefamulin DME6G97 Moderate Decreased metabolism of Rivaroxaban caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [34]
Choline salicylate DM8P137 Moderate Increased risk of bleeding by the combination of Rivaroxaban and Choline salicylate. Postoperative inflammation [1A00-CA43] [35]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Rivaroxaban caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [15]
Enzalutamide DMGL19D Major Increased metabolism of Rivaroxaban caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [14]
Darolutamide DMV7YFT Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [36]
Ixekizumab DMXW92T Moderate Altered metabolism of Rivaroxaban due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [13]
Tocilizumab DM7J6OR Moderate Altered metabolism of Rivaroxaban due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Rilonacept DMGLUQS Moderate Altered metabolism of Rivaroxaban due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Golimumab DMHZV7X Moderate Altered metabolism of Rivaroxaban due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Sarilumab DMOGNXY Moderate Altered metabolism of Rivaroxaban due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [13]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Rivaroxaban caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [15]
Tedizolid DMG2SKR Moderate Decreased clearance of Rivaroxaban due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [13]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Rivaroxaban caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [13]
Larotrectinib DM26CQR Moderate Decreased metabolism of Rivaroxaban caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
Armodafinil DMGB035 Minor Increased metabolism of Rivaroxaban caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
LEE011 DMMX75K Moderate Decreased metabolism of Rivaroxaban caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [15]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Rivaroxaban and Curcumin. Solid tumour/cancer [2A00-2F9Z] [38]
Plicamycin DM7C8YV Major Increased risk of bleeding by the combination of Rivaroxaban and Plicamycin. Testicular cancer [2C80] [12]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Rivaroxaban caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [39]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Rivaroxaban and Apixaban. Thrombosis [DB61-GB90] [12]
Cangrelor DM8JRH0 Major Increased risk of bleeding by the combination of Rivaroxaban and Cangrelor. Thrombosis [DB61-GB90] [13]
Brilinta DMBR01X Major Increased risk of bleeding by the combination of Rivaroxaban and Brilinta. Thrombosis [DB61-GB90] [12]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Rivaroxaban and Cabozantinib. Thyroid cancer [2D10] [40]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Rivaroxaban and Betrixaban. Venous thromboembolism [BD72] [12]
⏷ Show the Full List of 83 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Rivaroxaban 10 mg tablet 10 mg Oral Tablet Oral
Rivaroxaban 15 mg tablet 15 mg Oral Tablet Oral
Rivaroxaban 20 mg tablet 20 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6388).
2 Rivaroxaban FDA Label
3 Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19 (COVID-PREVENT)
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry. Basic Clin Pharmacol Toxicol. 2013 Mar;112(3):164-70.
7 Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study. Eur J Clin Pharmacol. 2019 Feb 6.
8 Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
9 Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40.
10 Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib. Chem Res Toxicol. 2021 Jul 19;34(7):1800-1813. doi: 10.1021/acs.chemrestox.1c00178. Epub 2021 Jun 30.
11 Price AJ, Frcpath DO "Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?" Ann R Coll Surg Engl 77 (1995): 395. [PMID: 7486773]
12 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
13 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
14 Canadian Pharmacists Association.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
17 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
18 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
19 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
20 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
21 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
22 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
23 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
24 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
25 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
26 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
27 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
28 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
29 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
30 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
31 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
32 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
33 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
34 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
35 Richards JR, Garber D, Laurin EG, et al. Treatment of cocaine cardiovascular toxicity: a systematic review.?Clin Toxicol (Phila). 2016;54(5):345-364. [PMID: 26919414]
36 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
37 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
38 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
39 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
40 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.